How Supplement Law Works: The DSHEA Premarket Gap

That small-print sentence on the back of the supplement bottle in your hand, "This statement has not been evaluated by the Food and Drug Administration," is doing more work than it looks. It is not a formality and it is not a warning that the product is dangerous. It is a precise legal marker telling you that no regulator checked the claim printed just above it. Understanding why that line has to be there, and what it does and does not mean, is the clearest window into how the United States regulates the entire supplement aisle.

Key points#

• Supplements are regulated as a category of food, not as drugs, so they carry no requirement for premarket approval.
• The manufacturer, not the FDA, is responsible for a product's safety and for truthful labeling before it is sold.
• Structure/function claims (such as "supports immune function") are legal without preapproval; disease claims (such as "treats arthritis") are not.
• The mandatory disclaimer signals that the specific claim was never reviewed, not that the product is unsafe and not that it works.

Where the rules come from#

The framework is the Dietary Supplement Health and Education Act of 1994, usually shortened to DSHEA. Its central move was a classification decision: it placed dietary supplements inside the legal category of food rather than the category of drugs. That single choice sets nearly everything else in motion, because food and drugs sit under opposite regulatory philosophies.

A prescription medicine cannot be sold until its sponsor has shown the FDA substantial evidence of both safety and effectiveness: the burden falls on the company, and the review happens first, before a single dose reaches a patient. Supplements run the tape backward. As the FDA states plainly on its dietary supplement pages, the agency does not approve supplements or their labeling before they are marketed. A company may formulate a product, write its label, and ship it, and only afterward does the government have a role.

The reversal that defines the gap#

The heart of the difference is who has to prove what, and when. For a drug, the maker must prove it works before launch, but for a supplement, the FDA must prove that a product already on shelves is unsafe or that its labeling is false before it can force a change. Nothing screens the product in advance. This is the premarket gap: the up-front review a drug goes through simply has no equivalent on the supplement side.

That does not leave supplements entirely unregulated. Manufacturers must follow current good manufacturing practice rules, must report serious adverse events, and must file a safety notification for any new dietary ingredient, meaning one not sold in the United States before October 1994. But every one of those safeguards operates after the product exists. They form a post-market safety net, with the agency reacting to problems rather than clearing products beforehand.

What a label is allowed to say#

DSHEA permits three broad kinds of claim on a supplement: nutrient content claims, health claims, and structure/function claims. The third kind is the one shoppers picture, and it is the least scrutinized of all; per the FDA's structure/function guidance, these statements may describe how a nutrient or ingredient contributes to normal structure or function of the body. "Supports immune function" and "helps maintain healthy cholesterol levels already within the normal range" are textbook examples.

The line that must not be crossed#

There is one hard boundary. The instant a label claims a product can diagnose, treat, cure, prevent, or mitigate a disease, the law reclassifies that product as a drug, and an unapproved one. "Supports joint comfort" stays inside the structure/function lane. "Treats arthritis" does not; it is a disease claim and is illegal without drug approval. This boundary explains most of the odd phrasing on supplement packaging. The physiology-flavored language is not sloppy marketing. It is the widest lane a company can stay in without tripping the drug rules.

Why notification is not the same as approval#

For a structure/function claim, the company must send the FDA a notification no later than 30 days after it first markets the product with that claim. The requirement lives at 21 CFR 101.93 and traces to section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act. Two features of that filing matter enormously.

First, it arrives after the product is already for sale, not before. Second, it is not a review of whether the claim is true. The company is required to hold substantiation that its claim is truthful and not misleading, but what it files with the agency is the wording of the claim, not the evidence behind it. The FDA recording a claim is bookkeeping. It is not a stamp of approval, and it was never meant to be read as one.

What the disclaimer is really telling you#

This is precisely why the disclaimer exists and why its language is fixed. 21 CFR 101.93 requires any structure/function claim to appear alongside a boldface statement: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Read literally, both sentences are simply true. No regulator vetted the claim, and the product is not an approved treatment for anything. The disclaimer neither warns that the product is harmful nor hints that it helps. It marks the edge of what was reviewed, and for the claim itself that edge is zero.

The placement rule is now being reconsidered. In a December 2025 letter to the dietary supplement industry, the FDA said it had received requests to amend the placement requirement at 21 CFR 101.93(d) and, absent significant concerns, is likely to propose a change, while exercising enforcement discretion in the meantime for the rule that the disclaimer appear on every panel carrying such a claim. Two things keep this in proportion. It is a proposal plus an enforcement posture, not a final rule, and it concerns where the disclaimer sits on the package, not whether the claim itself was ever evaluated. The meaning of the signal has not changed.

Turning a label into questions#

Once the gap is clear, a supplement label stops being a verdict and becomes a short list of questions you can ask. Is the wording a structure/function claim or a smuggled disease claim? Is there independent evidence for this ingredient at the dose actually used, or just a physiology-shaped sentence next to a disclaimer? Does "clinically studied" refer to the finished product, or to a single ingredient in an unrelated trial? The law does not certify that a supplement works. It certifies that the maker stayed inside the claim rules. Those are very different promises, and the disclaimer is the law's own reminder that they are not the same.